These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29276815)

  • 21. Enantioselective synthesis of PPAR (peroxisome proliferator-activated receptors) agonists and antagonists.
    Goya P; Perez-Fernandez R; Gonzalez-Muniz R; Elguero J
    Curr Top Med Chem; 2014; 14(10):1283-93. PubMed ID: 24758429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
    Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and Synthesis of 1,4-dihydropyridine Derivatives as Anti-cancer Agent.
    Viradiya D; Mirza S; Shaikh F; Kakadiya R; Rathod A; Jain N; Rawal R; Shah A
    Anticancer Agents Med Chem; 2017; 17(7):1003-1013. PubMed ID: 27924733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peroxisome proliferator-activated receptors as therapeutic targets for heart failure.
    Abushouk AI; El-Husseny MWA; Bahbah EI; Elmaraezy A; Ali AA; Ashraf A; Abdel-Daim MM
    Biomed Pharmacother; 2017 Nov; 95():692-700. PubMed ID: 28886529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease.
    Bisgaier CL; Oniciu DC; Srivastava RAK
    J Cardiovasc Pharmacol; 2018 Jul; 72(1):3-10. PubMed ID: 29621036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis.
    Han X; Wu Y; Yang Q; Cao G
    Pharmacol Ther; 2021 Jun; 222():107791. PubMed ID: 33321113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peroxisome proliferator-activated receptor (PPAR) and vitamin D receptor (VDR) signaling pathways in melanoma cells: promising new therapeutic targets?
    Sertznig P; Seifert M; Tilgen W; Reichrath J
    J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):383-6. PubMed ID: 20214982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.
    O'Sullivan SE
    Br J Pharmacol; 2007 Nov; 152(5):576-82. PubMed ID: 17704824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of peroxisome proliferator-activated receptors (PPARs) by PPAR(alpha)- and PPAR(gamma)-specific ligands and by 17beta-estradiol in isolated zebrafish hepatocytes.
    Ibabe A; Herrero A; Cajaraville MP
    Toxicol In Vitro; 2005 Sep; 19(6):725-35. PubMed ID: 15964169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A simple and reliable approach for assessing anticancer activity in vitro.
    López-Lázaro M
    Curr Med Chem; 2015; 22(11):1324-34. PubMed ID: 25666807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists.
    Grommes C; Landreth GE; Heneka MT
    Lancet Oncol; 2004 Jul; 5(7):419-29. PubMed ID: 15231248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The role of peroxisome proliferator-activated receptors (PPAR) in carcinogenesis].
    Knapp P; Jarzabek K; Błachnio A; Zbroch T
    Ginekol Pol; 2006 Aug; 77(8):643-51. PubMed ID: 17076197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the tumor stroma with peroxisome proliferator activated receptor (PPAR) agonists.
    Bundscherer A; Reichle A; Hafner C; Meyer S; Vogt T
    Anticancer Agents Med Chem; 2009 Sep; 9(7):816-21. PubMed ID: 19594413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C; Tsantili-Kakoulidou A; Theocharis S
    Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and development of oxazol-5-ones as potential partial PPAR-γ agonist against cancer cell lines.
    Pal T; Joshi H; Ramaa CS
    Anticancer Agents Med Chem; 2014; 14(6):872-83. PubMed ID: 24875128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.
    Tan CK; Zhuang Y; Wahli W
    Expert Opin Ther Targets; 2017 Mar; 21(3):333-348. PubMed ID: 28092722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The IkappaBalpha gene is a peroxisome proliferator-activated receptor cardiac target gene.
    Buroker NE; Barboza J; Huang JY
    FEBS J; 2009 Jun; 276(12):3247-55. PubMed ID: 19438714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peroxisome Proliferator-Activated Receptor Ligands and Their Role in Chronic Myeloid Leukemia: Therapeutic Strategies.
    Yousefi B; Samadi N; Baradaran B; Shafiei-Irannejad V; Zarghami N
    Chem Biol Drug Des; 2016 Jul; 88(1):17-25. PubMed ID: 26841308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting peroxisome proliferator-activated receptors: a novel strategy for Philadelphia chromosome-positive leukemia cells.
    Okabe S; Tauchi T; Tanaka Y; Ohyashiki K
    Leuk Lymphoma; 2017 Nov; 58(11):2762-2764. PubMed ID: 28504032
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.